Richter Gedeon (RIG2.F)

Executive Summary

Richter Gedeon is a leading Hungarian multinational pharmaceutical company with a core focus on women's healthcare and central nervous system (CNS) therapies. The company boasts a development pipeline of 34 drug candidates and markets products in over 100 countries. Its flagship product, cariprazine (marketed as Vraylar), is approved for schizophrenia and bipolar disorder, and the company continues to invest in expanding its indications. With a market capitalization of approximately $6.5 billion, Richter maintains a strong presence in Europe, CIS, and other regions, leveraging its full value chain from API production to finished dosage forms. Richter's near-term prospects hinge on the advancement of its pipeline, particularly the ongoing Phase 3 trial of cariprazine as an adjunctive therapy in schizophrenia (NCT03817502), expected to complete in late 2026. Positive results could strengthen its CNS franchise and drive revenue growth. Additionally, the company's experience in biosimilars (e.g., RGB-14-P for osteoporosis) and recent Phase 1 studies in diabetes suggest potential for portfolio expansion. However, reliance on a few key products and regulatory risks in emerging markets temper conviction. Overall, Richter is well-positioned in its niche therapeutic areas with a solid R&D foundation.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 top-line results for cariprazine in schizophrenia adjunctive therapy75% success